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Introduction
Temozolomide (Temodal) is a new alkylating cytostatic
agent, that has found its use in managing recurrent
malignant brain gliomas, predominantly in adult patients
[1-12]. The drug is administered orally as tablets at the
dose of 150-200 mg/m2/day over 5 days. The cycles are
repeated every 28 days. Temozolomide is rapidly absorbed
when administered orally and is spontaneously hydrolyzed
at physiologic pH to its active metabolite 3-methyl-
(triazen-1-yl) imidazole-4-carboximide (MTIC). The
mechanism of action of MTIC is thought to be alkylation
of the 06 position of guanine with additional alkylation
at the N7 position. In preclinical studies, temozolomide
has been shown to exert significant antitumor activity
against a variety of human central nervous system tumor
xenograft models [2-3, 5, 7, 9]. No accumulation occurs
with multiple daily dosing. temozolomide achieves higher
levels in human astrocytoma, as compared to the contrala-
teral normal brain [3]. In clinical studies temozolomide
has been shown to have 100% oral bioavailability and
extensive tissue distribution including penetration of the
blood-brain barrier [2-5, 7-12]. Dose-limiting toxicity
appears as myelosuppression, consisting of grade 3 or 4
thrombocytopenia and/or neutropenia. Platelet and
neutrophil count nadirs occur late in the cycle (usually
between days 21 and 28) and recovery is rapid within 1-2
weeks. Temozolomide is reported to cause a relatively
small number of adverse effects, mainly in the form
of decreased blood count index [2-5, 8, 9, 12]. In
a randomized multicenter phase II study temozolomide
vs. Procarbazine, 42% adult patients suffered nausea,
35% vomiting and 30% fatigue [4]. These side effects are
similar to other reports [3, 5, 11]. Reports indicate that
temozolomide has been employed in children in a few
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M a t e r i a l  a n d  m e t h o d s.  A new alkylating cytostatic drug – Temozolomide (Temodal) – was administered to 13 children
treated for malignant brain tumors between June 1999 and June 2002. The patients were followed up till November 2002. In
two cases Temozolomide was employed preoperatively as the first-order agent aiming to reduce the tumor mass, while
11 patients received Temozolomide following the failure of previous standard therapy.
Re s u l t s.  Complete and almost complete regression was achieved in 2 cases. A short-term regression or stabilization of tumor
size lasting 2-12 months was noted in 3 children. Five patients showed no therapeutic effect and further tumor progression
occurred. In two patients the therapy was discontinued. In preoperative patients Temozolomide was successful in one patient.
C o n c l u s i o n s.  Temozolomide was successful in 3 patients while in 3 children the disease stabilized for a period of 2-12
months.
Temozolomide w leczeniu z∏oÊliwych guzów mózgu u dzieci
M a t e r i a ∏  i m e t o d y.  U 13 dzieci leczonych z powodu z∏oÊliwych guzów mózgu w okresie od czerwca 1999 r. do czerwca
2002 r. zastosowano nowy cytostatyk, alkilujàcy temozolomide (Temodal). Kontrol´ pacjentów po leczeniu prowadzono do
listopada 2002 r. W dwóch przypadkach temozolomide zastosowano przedoperacyjnie, celem zmniejszenia masy guza,
podczas gdy 11 pacjentów otrzyma∏o temozolomide z powodu niepowodzenia standardowej terapii.
W y n i k i.  Ca∏kowità i prawie ca∏kowità regresj´ otrzymano w 2 przypadkach. Krótkotrwa∏à regresj´ lub stabilizacj´ masy guza,
trwajàcà od 2 do 12 miesi´cy, odnotowano u 3 dzieci. U 5 dzieci nie wykazano terapeutycznego efektu i wystàpi∏a progresja
choroby. U 2 pacjentów leczenie przerwano. U pacjentów, u których Temozolomide zastosowano przedoperacyjnie, lek
okaza∏ si´ skuteczny u jednego.
W n i o s k i.  Temozolomide wydaje si´ byç skuteczny u 3 leczonych pacjentów. U 3 dzieci stabilizacja choroby utrzyma∏a si´
przez okres 2-12 miesi´cy.
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centers and only fewer than 100 patients worldwide have
received the drug, not only in relapsed brain gliomas, but
also in medulloblastomas and PNET tumors [13, 18].
Material and methods
Temozolomide therapy was commenced at the University
Children's Hospital of Cracow in June 1999. The treatment
program included 13 patients (7 girls and 6 boys) aged 3-19
years (mean age 10.6 years). In cases of pineoblastoma specimens
for histopathology were obtained by a stereotactic biopsy, while
in the remaining patients specimens were collected intraoperati-
vely, during open neurosurgical procedures. Table I presents
the patients and their histopathological diagnoses.
Table I. Histopathological findings in children with brain tumors
Histopathology No. of patients
Medulloblastoma 3
Pineoblastoma 1
Glioblastoma multiforme 3
Anaplastic astrocytoma 3
Fibrillary astrocytoma with single cellular atypia foci 2
Brainstem glioma 1
Temozolomide was administered orally every 28 days for 5
days at the dose of 150-200 mg/m2, depending on blood cell
count values and previous chemotherapy. In the group with no
effect after standard treatment (2 children) or with relapsed
disease (9 patients) no more than 6 cycles were given. In the
group with preoperative chemotherapy (2 children), 3 courses of
chemotherapy were prescribed. In the case of progression of
the disease the treatment was discontinued.
Pa t i e n t s
Medulloblastoma
Temozolomide was employed in 3 children: a 9-year old boy
treated 6 months earlier because of his T2M1 disease according
to Chang, a 6-year old girl with a T3AM1 tumor and a 10-year
old boy with advanced T3AM1 disease. All the children had
been previously subjected to chemotherapy and total CNS
irradiation therapy with an increased dose applied to the tumor
site. The patients relapsed within 6 months to 4 years after the
completion of treatment. All the children had disseminated
disease. They presented with severe pain involving the
lumbosacral segment of the spine.
Pineoblastoma
A 15-year old girl with pineoblastoma: one year after the comple-
tion of chemotherapy and irradiation therapy, CT and MRI
revealed persistent residual tumor mass.
M a l i g n a n t  b r a i n  g l i o m a s
Relapses at the tumor site were detected in 5 children. No total
regression after standard treatment was observed in two patients.
Two (a 14-year old girl and a boy) had grade III (WHO)
malignant astrocytomas. Both patients had been previously
treated surgically and subjected to irradiation therapy. The girl
manifested tumor regrowth at the original site one year after
radiotherapy completion. The patient was reoperated and
according to the operator the tumor mass was completely
resected. The 14-year old boy with a malignant brainstem
astrocytoma had undergone a non-radical tumor excision and
subsequently irradiation therapy. Two months after radiotherapy,
tumor regrowth occurred. The third patient was a 19-year old
girl with glioblastoma multiforme presented with massive
tumor regrowth one year after radiotherapy completion. The
patient was reoperated and according to the operator, macro-
scopically the mass was completely resected. Another patient
was a 10-year old boy treated surgically and irradiated in our
center due to a grade III (WHO) malignant brain glioma. Seven
years later tumor regrowth was detected at the tumor site
and a radical surgery as attested by the operator followed.
Intraoperative histopathology revealed a glioblastoma multiforme
type tumor.
Three children were diagnosed with brainstem gliomas,
including two with histologically confirmed brainstem fibrillary
astrocytomas with isolated atypia foci. These included a 6-year old
boy previously subjected to chemotherapy and radiotherapy in
another center and a 14-year old girl treated with irradiation
therapy alone. Less than one year after treatment completion,
the boy manifested massive tumor regrowth. The patient was
reoperated and tumor mass situated in the central and superior
pons was partially resected. In the case of the second patient,
apart from a brainstem tumor, she also revealed neoplastic
cells within the spinal canal. Following irradiation therapy
involving the entire central nervous system with an increased
dose applied to the tumor site, the child presented with complete
regression within the spinal canal and partial regression of
brainstem mass.
The third patient was a 7-year old boy with diffuse
brainstem glioma. The tumor was partially resected with residual
brainstem malignancy after irradiation therapy.
P r e o p e r a t i v e  t e m o z o l o m i d e  a d m i n i s t r a t i o n
The drug was employed in two girls. One of them was a 3-year
old patient with a CT and MRI-confirmed extensive brainstem
tumor suggestive of a markedly malignant glioma. The other
patient was a 12-year old girl with a CT and MRI-confirmed
malignant brainstem glioma.
Results of temozolomide chemotherapy
In the group of patients in whom standard therapy
had failed, total and almost total tumor regression
following temozolomide chemotherapy was achieved
in two children, namely in a girl with pineoblastoma and
in another female patient with brainstem fibrillary
astrocytoma with cellular atypia. Any evaluation of this
outcome is difficult, since post-radiotherapy residual
lesions may undergo a slow, long-term remission. In seven
children temozolomide failed to prevent further tumor
progression. In two patients the therapy was discontinued.
This group included a boy with diffuse brainstem glioma
who developed grade IV WHO bone marrow aplasia
after the first cycle, and a 19-year old girl with relapsed
glioblastoma multiforme, who died in a regional hospital
due to subarachnoid hemorrhage. In the two children in
whom temozolomide was administered preoperatively,
a therapeutic effect was achieved in one patient. The girl
was operated on and intraoperative histopathology
revealed a glioblastoma multiforme-like malignancy with
numerous post-chemotherapy necrotic foci. Table II.
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Discussion
Data originating from clinical temozolomide trials suggest
that the drug evokes a relatively small number of adverse
effects and is particularly well tolerated by children when
administered orally [3, 4, 6, 11-18]. Unfortunately,
communications of temozolomide employed in relapsed
brain malignancies in children are still scarce, and the
analyzed groups of patients are small [13-18]. Data on
temozolomide therapy originate mostly from adult
centers. A multicenter, randomized clinical trial carried
out in large groups of adult patients has demonstrated
that temozolomide is more effective in treating relapsed
glioblastoma multiforme than Procarbazine. The 6-month
overall survival in the temozolomide group was 60%,
while in the Procarbazine patients the corresponding
value was 44% only [4]. In his clinical study of 48 adult
patients with recurrent anaplastic oligodendrogliomas, who
had been previously treated with irradiation therapy
and PCV chemotherapy (Procarbazine, Lomustine and
Vincristine), Chinot employed temozolomide and de-
monstrated a complete response in 16.7% patients,
a partial response in 27.1% and a stable disease in
39.6% [12]. Also the quality of life improves in patients
on temozolomide, and the time lapse before disease
progression occurs is prolonged. This has been demon-
strated by the largest to-date clinical trial carried out in
525 adult patients with relapsed malignant gliomas [5].
Other clinical studies have pointed to a low therapeutic
effectiveness of temozolomide in the treatment of
malignant brain gliomas, but with a clear improvement
in the quality of life [6, 10, 11].
In the investigated group of 11 children with relapsed
malignant brain tumors or after standard therapy failures,
temozolomide seems to be successful in two patients
(18%). Once again it is difficult to evaluate this outcome,
since both patients who were administered temozolomide
had persistent residual tumor mass fragments following
standard radiotherapy. Possibly the reaction to
temozolomide therapy is found in a slow tumor mass
regression following irradiation therapy. A doubtlessly
positive palliative effect has been achieved in three
children with medulloblastoma, who demonstrated
resolution of such symptoms as headache, nausea,
vomiting, balance disturbances and severe sacrolumbar
pain, observed already after the first cycle of therapy. For
the period of 2-12 months these patients were in a very
good general state and asymptomatic. The drug inhibited
the neoplastic process for this time and the patients were
able to function without any symptoms of the disease.
Other patients showed a brief clinical improvement
following temozolomide therapy, yet the drug did not
Table II. Outcome of temozolomide therapy in children with malignant brain tumors
Histopathology Sex Age Cause of No of Duration of Outcome
Temodal treatment Temodal cycles symptom 
stabilization
Glioblastoma multiforme F 19 years Tumor relapse I Symptom-free Death because of 
subarachnoid hemorrhage
M 10 years II 1,5 month Progression
Death
Anaplastic astrocytoma M 14 years II No effect Progression
Death
F 14 years II 1 month Progression
Death
Fibrillare astrocytoma M 6 years II No effect Progression
with cellular atypia Death
Medulloblastoma M 9 years Tumor relapse III 2 months Progression
Death
M 10 years IV 6 months Progression
Death
F 6 years VI 12 months Progression
Death
Brainstem glioma M 7 years No total tumor regression I Lost to the study
after standard treatment
Fibrillare astrocytoma F 14 years VI Symptom-free Regression
with cellular atypia Alive near 3 years
Pineoblastoma F 15 years VI Symptom-free Total regression 
Alive 2,5 years
Anaplastic astrocytoma F 12 years Neoadjuvant treatment II No effect Progression
Glioblastoma multiforme F 3 years III Regression of symptoms Tumor shrinkage
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prevent further progress of the disease. Nevertheless,
aware of the fact that the investigated group of patients
consisted of individuals without any chances for a cure, we
believe that the use of temozolomide in order to achieve
even brief remissions allowing the children to be pain-
free and capable of normal functioning was justified. No
temozolomide -associated toxicity was noted in two
children. Four children showed mild bone marrow toxicity
of grade II (WHO). Five patients manifested grade
III bone marrow aplasia (WHO), while one showed grade
IV aplasia and treatment was discontinued. A 19-year
old patient died due to a subarachnoid hemorrhage
showing no histopathological signs of bone marrow
aplasia.
Of two children subjected to preoperative
temozolomide chemotherapy, partial tumor regression
was achieved in one.
Our results are similar to data from pediatric centers
where temozolomide was employed in children. Unfor-
tunately, such reports are still too scarce and predo-
minantly of a preliminary character.
Conclusions
– In view of its oral route of administration,
temozolomide is a well tolerated form of chemo-
therapy in children.
– In 3 children with medulloblastoma stabilization of the
disease was achieved, for a period of 2 to 12 months
and allowed the patients to be pain-free and to
function normally.
– The paper sums up the observations of 13 patients.
The issue of temozolomide effectivness in children
with malignant brain tumors reguires futher studies in
a more numerous group of patients.
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